Thymidine Kinase Gene Delivery Using Curcumin Loaded Peptide Micelles as a Combination Therapy for Glioblastoma

Park, Jin Hyeong; Han, Jaesik; Lee, Minhyung

doi:10.1007/s11095-014-1482-4

Cited by 18 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the previous study, R7L10 was evaluated as a gene carrier for the lung . R7L10 was also evaluated as a gene carrier for tumor animal models . Therefore, the first purpose of the current study was to confirm that R7L10 delivered pEpo–NI2–SV–HSVtk into the tumor and elicited the therapeutic effects.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Peptide Micelle-Mediated Delivery of Tissue-Specific Suicide Gene and Combined Therapy with Avastin in a Glioblastoma Model

Han

Choi

et al. 2015

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 89%

“…12 R7L10 was also evaluated as a gene carrier for tumor animal models. 33 Therefore, the first purpose of the current study was to confirm that R7L10 delivered pEpo-NI2-SV-HSVtk into the tumor and elicited the therapeutic effects. In Figure 7, the pEpo-NI2-SV-HSVtk/R7L10 complexes inhibited the tumor growth at all tested doses.…”

Section: Discussionmentioning

confidence: 90%

Peptide Micelle-Mediated Delivery of Tissue-Specific Suicide Gene and Combined Therapy with Avastin in a Glioblastoma Model

Han

Choi

et al. 2015

Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

“…Our previous study showed that HSV-TK/GCV treatment induced cell apoptosis and inhibited tumor growth (Xiao et al 2018). By loading curcumin into the P7L10 peptide micelles to be a more efficient carrier for HSV-TK gene delivery, Park et al reported that HSV-tk/R7L10-Cur complex induced C6 rat glioblastoma cell death and reduced the tumor size of xenografted glioblastoma (Park et al 2015). However, the mechanism was not studied and the dose of curcumin was not demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Peer Review #2 of "Curcumin plays a synergistic role in combination with HSV-TK/GCV in inhibiting growth of murine B16 melanoma cells and melanoma xenografts (v0.1)"

2019

View full text Add to dashboard Cite

Melanoma is a global concern and accounts for the major mortality of skin cancers. Herpes simplex virus thymidine kinase gene with ganciclovir (HSV-TK/GCV) is a promising gene therapy for melanoma. Despite its low efficiency, it is well known for its bystander effect which is mainly mediated by gap junction. In this study, we found that curcumin reduced B16 melanoma cell viability in both time-and dose-dependent manner. Further study showed that curcumin improved the gap junction intercellular communication (GJIC) function, and upregulated the proteins essential to gap junction, such as connexin 32 and connexin 43, indicating the potential role in enhancing the bystander effect of HSC-TK/GCV. By co-culturing the B16 TK cells, which stably expressed TK gene, with wildtype B16 (B16 WT) cells, we found that co-treatment of curcumin and GCV synergistically inhibited B16 cell proliferation, but the effect could be eliminated by the gap junction inhibitor AGA. Moreover, curcumin markedly increased apoptosis rate of B16 WT cells, suggesting its effect in enhancing the bystander effect of HSV-TK/GCV. In the in-vivo study, we established the xenografted melanoma model in 14 days by injecting mixture of B16 TK and B16 WT cell in a ratio of 3:7. The result demonstrated that, co-administration of curcumin and GCV significantly inhibited the xenograft growth, as indicated by the smaller size and less weight. The combinational effect was further confirmed as a synergistic effect. In conclusion, the results demonstrated that curcumin could enhance the killing effect and the bystander effect of HSV-TK/GCV in treating melanoma, which might be mediated by improved gap junction. Our data suggested that combination of HSV-TK/GCV with curcumin could be a potential chemosensitization strategy for cancer treatment.

show abstract

“…The in-vivo results showed that R7L10-curcumin delivered pDNA with better efficiency and reduced the TNF-a level in lung tissues in an acute lung injury mouse model [166]. Similarly, to assess the effect of combination therapy, CUR was delivered along with herpes simplex virus thymidine kinase (HSVtk) gene using R7L10 peptide micelles as a carrier in glioblastoma animal model [167]. CUR was found to deliver more efficiently into cells by R7L10-CUR micelles than CUR alone.…”

Section: Polymeric Micellesmentioning

confidence: 99%

“…CUR was found to deliver more efficiently into cells by R7L10-CUR micelles than CUR alone. R7L10-CUR micelles induced cell death efficiently in in-vitro as well as in-vivo study [167]. Recently, Martin et al [168] accounted simultaneous loading of lipophilic gold nanorods (GNRs) and CUR into polymeric nanomicelles prepared from biocompatible PLGA-b-PEG copolymer for efficient in-vivo photothermal therapy of Barrett Esophagus.…”

Section: Polymeric Micellesmentioning

confidence: 99%

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

Ahmad

Alkahtani

Akhter

et al. 2015

Journal of Drug Targeting

View full text Add to dashboard Cite

Comprehensive pharmacological screening of curcumin (CUR) has given the evidence that it is an excellent naturally occurring therapeutic moiety for cancer. It is very well tolerated with insignificant toxicity even after high doses of oral administration. Irrespective of its better quality as an anticancer agent, therapeutic application of CUR is hampered by its extremely low-aqueous solubility and poor bioavailability, rapid clearance and low-cellular uptake. A simple means of breaking up the restrictive factor of CUR is to perk-up its aqueous solubility, improve its bioavailability, protect it from degradation, and metabolism and potentiate its targeting capacity towards the cancer cell. The development in the field of nanomedicine has made excellent progresses toward enhancing the bioavailability of lipophilic drugs like CUR. Nanoparticles (NPs) are capable to deliver the CUR at specific area and thereby prevent it from physiological degradation and systemic clearance. In recent year, an assortment of nanomedicine-based novel drug delivery system has been designed to potentiate the bioavailability of CUR towards anticancer therapy. In this review, we discuss the recent development in the field of nanoCUR (NanoCur), including polymeric micelles, liposome, polymeric NPs, nanoemulsion, nanosuspension, solid lipid NPs (SLNPs), polymer conjugates, nanogel, etc. in anticancer application.

show abstract

Thymidine Kinase Gene Delivery Using Curcumin Loaded Peptide Micelles as a Combination Therapy for Glioblastoma

Abstract: R7L10 is an efficient carrier for delivery of curcumin and the HSVtk gene, which may be a useful combination therapy for glioblastoma.

Cited by 18 publications

References 26 publications

Peptide Micelle-Mediated Delivery of Tissue-Specific Suicide Gene and Combined Therapy with Avastin in a Glioblastoma Model

Peptide Micelle-Mediated Delivery of Tissue-Specific Suicide Gene and Combined Therapy with Avastin in a Glioblastoma Model

Peer Review #2 of "Curcumin plays a synergistic role in combination with HSV-TK/GCV in inhibiting growth of murine B16 melanoma cells and melanoma xenografts (v0.1)"

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

Contact Info

Product

Resources

About